252 related articles for article (PubMed ID: 31563929)
1. The strong case for government funding of a polypill for the secondary prevention of cardiovascular disease in New Zealand.
Selak V; Bullen C; Arroll B; Doughty R; Doughty R; Grey C; Harwood M; Crengle S
N Z Med J; 2019 Sep; 132(1502):77-83. PubMed ID: 31563929
[TBL] [Abstract][Full Text] [Related]
2. Combined use of polypill components in patients with type 2 diabetes mellitus.
Janssen VE; Visseren FL; de Boer A; Grobbee DE; Westerink J; van der Graaf Y; Lafeber M;
Eur J Prev Cardiol; 2018 Sep; 25(14):1523-1531. PubMed ID: 30033753
[TBL] [Abstract][Full Text] [Related]
3. Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials.
Selak V; Webster R; Stepien S; Bullen C; Patel A; Thom S; Arroll B; Bots ML; Brown A; Crengle S; Dorairaj P; Elley CR; Grobbee DE; Harwood M; Hillis GS; Laba TL; Neal B; Peiris D; Rafter N; Reid C; Stanton A; Tonkin A; Usherwood T; Wadham A; Rodgers A
Heart; 2019 Jan; 105(1):42-48. PubMed ID: 29954855
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial.
Singh K; Crossan C; Laba TL; Roy A; Hayes A; Salam A; Jan S; Lord J; Tandon N; Rodgers A; Patel A; Thom S; Prabhakaran D
Int J Cardiol; 2018 Jul; 262():71-78. PubMed ID: 29622506
[TBL] [Abstract][Full Text] [Related]
5. The concept of the polypill in the prevention of cardiovascular disease.
Wiley B; Fuster V
Ann Glob Health; 2014; 80(1):24-34. PubMed ID: 24751562
[TBL] [Abstract][Full Text] [Related]
6. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
[TBL] [Abstract][Full Text] [Related]
7. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
[TBL] [Abstract][Full Text] [Related]
8. The polypill: An effective approach to increasing adherence and reducing cardiovascular event risk.
Bramlage P; Sims H; Minguet J; Ferrero C
Eur J Prev Cardiol; 2017 Feb; 24(3):297-310. PubMed ID: 27798363
[TBL] [Abstract][Full Text] [Related]
9. Could the polypill improve adherence? The patient perspective.
Bryant L; Martini N; Chan J; Chang L; Marmoush A; Robinson B; Yu K; Wong M
J Prim Health Care; 2013 Mar; 5(1):28-35. PubMed ID: 23457692
[TBL] [Abstract][Full Text] [Related]
10. Strengths and Limitations of Using the Polypill in Cardiovascular Prevention.
Roy A; Naik N; Srinath Reddy K
Curr Cardiol Rep; 2017 May; 19(5):45. PubMed ID: 28425033
[TBL] [Abstract][Full Text] [Related]
11. The Effect of a Cardiovascular Polypill Strategy on Pill Burden.
Truelove M; Patel A; Bompoint S; Brown A; Cass A; Hillis GS; Peiris D; Rafter N; Reid CM; Rodgers A; Tonkin A; Usherwood T; Webster R;
Cardiovasc Ther; 2015 Dec; 33(6):347-52. PubMed ID: 26280247
[TBL] [Abstract][Full Text] [Related]
12. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of fixed dose combination medication ('polypills') compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries.
Webster R; Patel A; Selak V; Billot L; Bots ML; Brown A; Bullen C; Cass A; Crengle S; Raina Elley C; Grobbee DE; Neal B; Peiris D; Poulter N; Prabhakaran D; Rafter N; Stanton A; Stepien S; Thom S; Usherwood T; Wadham A; Rodgers A;
Int J Cardiol; 2016 Feb; 205():147-156. PubMed ID: 26736090
[TBL] [Abstract][Full Text] [Related]
14. Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.
Gaziano TA; Pandya A; Sy S; Jardim TV; Ogden JM; Rodgers A; Weinstein MC
Am Heart J; 2019 Aug; 214():77-87. PubMed ID: 31174054
[TBL] [Abstract][Full Text] [Related]
15. The cardiovascular polypill in high-risk patients.
Lafeber M; Spiering W; Singh K; Guggilla RK; Patil V; Webster R;
Eur J Prev Cardiol; 2012 Dec; 19(6):1234-42. PubMed ID: 22019908
[TBL] [Abstract][Full Text] [Related]
16. The feasibility of polypill for cardiovascular disease prevention in Asian Population.
Sukonthasarn A; Chia YC; Wang JG; Nailes J; Buranakitjaroen P; Van Minh H; Verma N; Hoshide S; Shin J; Turana Y; Tay JC; Teo BW; Siddique S; Sison J; Zhang YQ; Wang TD; Chen CH; Kario K
J Clin Hypertens (Greenwich); 2021 Mar; 23(3):545-555. PubMed ID: 33086429
[TBL] [Abstract][Full Text] [Related]
17. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.
Thom S; Field J; Poulter N; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Rodgers A
Eur J Prev Cardiol; 2014 Feb; 21(2):252-61. PubMed ID: 23038750
[TBL] [Abstract][Full Text] [Related]
18. The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) in clinical practice in patients with vascular diseases or type 2 diabetes mellitus.
Lafeber M; Grobbee DE; Spiering W; van der Graaf Y; Bots ML; Visseren FL;
Eur J Prev Cardiol; 2013 Oct; 20(5):771-8. PubMed ID: 22649123
[TBL] [Abstract][Full Text] [Related]
19. Polypill treatments for cardiovascular diseases.
Webster R; Rodgers A
Expert Opin Drug Deliv; 2016; 13(1):1-6. PubMed ID: 26558898
[TBL] [Abstract][Full Text] [Related]
20. Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis.
Zomer E; Owen A; Magliano DJ; Ademi Z; Reid CM; Liew D
Am J Cardiovasc Drugs; 2013 Apr; 13(2):121-8. PubMed ID: 23532687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
